इओसिनोफिलिक फैसाइटिस का उपचार: लक्षित जैविक और सहायक रणनीतियाँ

References

DOI: 10.1007/s40674-024-00222-6

• IL-6 blocking by a humanized monoclonal antibody, tocilizumab, recently has gained interest in the treatment of EF when other more conventional agents such as methotrexate or mycophenolate mofetil are not working as a second-line glucocorticoid-sparing agents.
• A total of 8 cases of patients with refractory EF have been reported who successfully respond to rituximab. Thus, this biological therapy could be a therapeutical option in severe and refractory cases of EF.
• Patients with EF refractory to conventional therapy have been reported with a successful response to any one of the JAK inhibitors, baricitinib or tofacitinib.
• It is well-known that IL-5 plays a role in the maturation, recruitment, and proliferation of eosinophils, thus it seems logical that monoclonal antibodies directed to the cytokine (mepolizumab or reslizumab, human monoclonal antibodies against IL-5) or to their receptor (benralizumab) may be useful in some cases that do not respond to the usual therapy with prednisone or immunosuppressive drugs.
• At least in those patients with sustained peripheral eosinophilia.
• UVA-1 phototherapy or irradiation (90 J/cm, for 40 consecutive sessions, 3–4 times a week) is an alternative therapy for difficult cases of EF.